Chemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy

Gabriel Ramirez; Ashley R Proctor; Ki Won Jung; Tong Tong Wu; Songfeng Han; Russell R Adams; Jingxuan Ren; Daniel K Byun; Kelley S Madden; Edward B Brown; Thomas H Foster; Parisa Farzam; Turgut Durduran; Regine Choe

doi:10.1364/BOE.7.003610

Chemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy

Biomed Opt Express. 2016 Aug 24;7(9):3610-3630. doi: 10.1364/BOE.7.003610. eCollection 2016 Sep 1.

Authors

Affiliations

¹ Department of Biomedical Engineering, University of Rochester, Rochester, NY 14627, USA.
² Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY 14642, USA.
³ The Institute of Optics, University of Rochester, Rochester, NY 14627, USA.
⁴ Department of Biomedical Engineering, University of Rochester, Rochester, NY 14627, USA; The Institute of Optics, University of Rochester, Rochester, NY 14627, USA; Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY 14642, USA.
⁵ ICFO- Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, 08860 Castelldefels (Barcelona), Spain.
⁶ ICFO- Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, 08860 Castelldefels (Barcelona), Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08015 Barcelona, Spain.
⁷ Department of Biomedical Engineering, University of Rochester, Rochester, NY 14627, USA; Department of Electrical and Computer Engineering, University of Rochester, Rochester, NY 14627, USA.

Abstract

The non-invasive, in vivo measurement of microvascular blood flow has the potential to enhance breast cancer therapy monitoring. Here, longitudinal blood flow of 4T1 murine breast cancer (N=125) under chemotherapy was quantified with diffuse correlation spectroscopy based on layer models. Six different treatment regimens involving doxorubicin, cyclophosphamide, and paclitaxel at clinically relevant doses were investigated. Treatments with cyclophosphamide increased blood flow as early as 3 days after administration, whereas paclitaxel induced a transient blood flow decrease at 1 day after administration. Early blood flow changes correlated strongly with the treatment outcome and distinguished treated from untreated mice individually for effective treatments.

Keywords: (170.3660) Light propagation in tissues; (170.6480) Spectroscopy, speckle; (290.4210) Multiple scattering.

Abstract

Grants and funding